234 related articles for article (PubMed ID: 17914247)
1. Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury.
Whaley-Connell A; DeMarco VG; Lastra G; Manrique C; Nistala R; Cooper SA; Westerly B; Hayden MR; Wiedmeyer C; Wei Y; Sowers JR
Am J Nephrol; 2008; 28(1):67-75. PubMed ID: 17914247
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment.
Whaley-Connell A; Habibi J; Nistala R; Cooper SA; Karuparthi PR; Hayden MR; Rehmer N; DeMarco VG; Andresen BT; Wei Y; Ferrario C; Sowers JR
Hypertension; 2008 Feb; 51(2):474-80. PubMed ID: 18172055
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat.
Whaley-Connell AT; Chowdhury NA; Hayden MR; Stump CS; Habibi J; Wiedmeyer CE; Gallagher PE; Tallant EA; Cooper SA; Link CD; Ferrario C; Sowers JR
Am J Physiol Renal Physiol; 2006 Dec; 291(6):F1308-14. PubMed ID: 16788142
[TBL] [Abstract][Full Text] [Related]
4. Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells.
Whaley-Connell AT; Morris EM; Rehmer N; Yaghoubian JC; Wei Y; Hayden MR; Habibi J; Stump CS; Sowers JR
Am J Nephrol; 2007; 27(1):15-23. PubMed ID: 17204833
[TBL] [Abstract][Full Text] [Related]
5. [A treatment with rosuvastatin induced a reduction of arterial pressure and a decrease of oxidative stress in spontaneously hypertensive rats].
Sicard P; Lauzier B; Oudot A; Busseuil D; Collin B; Duvillard L; Moreau D; Vergely C; Rochette L
Arch Mal Coeur Vaiss; 2005; 98(7-8):804-8. PubMed ID: 16220751
[TBL] [Abstract][Full Text] [Related]
6. eNOS/Hsp70 interaction on rosuvastatin cytoprotective effect in neonatal obstructive nephropathy.
Manucha W; Kurbán F; Mazzei L; Benardón ME; Bocanegra V; Tosi MR; Vallés P
Eur J Pharmacol; 2011 Jan; 650(2-3):487-95. PubMed ID: 20940012
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion.
Park JK; Mervaala EM; Muller DN; Menne J; Fiebeler A; Luft FC; Haller H
J Hypertens; 2009 Mar; 27(3):599-605. PubMed ID: 19262227
[TBL] [Abstract][Full Text] [Related]
8. Effect of rosuvastatin on capillary filtration of albumin and blood pressure in rats with streptozotocin-induced diabetes.
Tarhzaoui K; Valensi P; Boulakia FC; Lestrade R; Albertini JP; Behar A
Diabetes Res Clin Pract; 2008 Jun; 80(3):335-43. PubMed ID: 18406000
[TBL] [Abstract][Full Text] [Related]
9. Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
Oltman CL; Kleinschmidt TL; Davidson EP; Coppey LJ; Lund DD; Yorek MA
Vascul Pharmacol; 2008 Jan; 48(1):47-53. PubMed ID: 18164667
[TBL] [Abstract][Full Text] [Related]
10. Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation.
Corna D; Sangalli F; Cattaneo D; Carrara F; Gaspari F; Remuzzi A; Zoja C; Benigni A; Perico N; Remuzzi G
Am J Nephrol; 2007; 27(6):630-8. PubMed ID: 17851231
[TBL] [Abstract][Full Text] [Related]
11. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Blanco S; Vaquero M; Gómez-Guerrero C; López D; Egido J; Romero R
Am J Hypertens; 2005 Apr; 18(4 Pt 1):557-65. PubMed ID: 15831368
[TBL] [Abstract][Full Text] [Related]
12. The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose.
Piconi L; Corgnali M; Da Ros R; Assaloni R; Piliego T; Ceriello A
J Diabetes Complications; 2008; 22(1):38-45. PubMed ID: 18191076
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
Schäfer A; Fraccarollo D; Eigenthaler M; Tas P; Firnschild A; Frantz S; Ertl G; Bauersachs J
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1071-7. PubMed ID: 15761193
[TBL] [Abstract][Full Text] [Related]
14. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.
Kostapanos MS; Milionis HJ; Lagos KG; Rizos CB; Tselepis AD; Elisaf MS
Eur J Pharmacol; 2008 Aug; 590(1-3):327-32. PubMed ID: 18585701
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia.
Ott C; Ritt M; Titze SI; Schäufele T; Schmieder RE
J Nephrol; 2009; 22(5):675-81. PubMed ID: 19810001
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice.
Verreth W; De Keyzer D; Davey PC; Geeraert B; Mertens A; Herregods MC; Smith G; Desjardins F; Balligand JL; Holvoet P
Br J Pharmacol; 2007 Jun; 151(3):347-55. PubMed ID: 17384667
[TBL] [Abstract][Full Text] [Related]
17. Effect of rosuvastatin on obesity-induced cardiac oxidative stress in Wistar rats--a preliminary study.
Ansari JA; Bhandari U; Pillai KK; Haque SE
Indian J Exp Biol; 2012 Mar; 50(3):216-22. PubMed ID: 22439437
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.
Desjardins F; Sekkali B; Verreth W; Pelat M; De Keyzer D; Mertens A; Smith G; Herregods MC; Holvoet P; Balligand JL
Eur Heart J; 2008 Jan; 29(1):128-37. PubMed ID: 18063594
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent effect of rosuvastatin treatment on urinary protein excretion.
Kostapanos MS; Milionis HJ; Saougos VG; Lagos KG; Kostara C; Bairaktari ET; Elisaf MS
J Cardiovasc Pharmacol Ther; 2007 Dec; 12(4):292-7. PubMed ID: 18172223
[TBL] [Abstract][Full Text] [Related]
20. Renal and metabolic effects of tempol in obese ZSF1 rats--distinct role for superoxide and hydrogen peroxide in diabetic renal injury.
Rafikova O; Salah EM; Tofovic SP
Metabolism; 2008 Oct; 57(10):1434-44. PubMed ID: 18803950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
